MedPath

Asthma Control-A "Patient Follow up Programme" Maintenance and Reliever Therapy in a Single Inhaler

Completed
Conditions
Asthma
Registration Number
NCT00524641
Lead Sponsor
AstraZeneca
Brief Summary

To investigate the change in patient's asthma symptom control using ACQ scores after 4 to 6 weeks of Symbicort Turbuhaler (budesonide/ formoterol) in SMART approach.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1254
Inclusion Criteria
  • Asthma patients from both sexes, age 18 or older
  • Have already been on Symbicort SMART treatment
  • Willing to give written informed consents to participate in the program.
Read More
Exclusion Criteria
  • Patients who are not willing to give written informed consent
  • Patients in emergency care for asthma at ICUs or COPD patients are excluded from the program.
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Research Site

🇻🇳

Ho Chi Minh City, Vietnam

© Copyright 2025. All Rights Reserved by MedPath